Search

Showing 31 - 40 of 514 results.

Patients who benefit

PATIENTS WHO BENEFIT MR IS THE MOST COMMON VALVULAR HEART DISEASE AND IS SIGNIFICANTLY UNDERTREATED3 More patients are suffering from MR than any other valve disease, and only a small percentage
Overview

LEARN MORE: AMPLATZER™ DUCT OCCLUDERS AMPLATZER™ PICCOLO™ OCCLUDER WATCH ON-DEMAND: PDA Symposium 2024 If PDA is left untreated, the mortality rate is 20% by age 20 years,
Prevention

AF AND THE CHALLENGES OF MEDICATION Many patients at risk of stroke want an alternative to oral anticoagulants (OACs), for example, warfarin and non-vitamin K oral anticoagulants (NOACs).7 40% Do N
Diagnosis

AF AND STROKE ARE OFTEN CONNECTED MORE SEVERE LEARN MORE: PATIENTS WHO BENEFIT Clinical Data
Overview

TRI-SCORE RISK SCORE MODEL FOR ISOLATED TRICUSPID VALVE SURGERY Secondary TR arising from RV remodelling can be classified in three progressive stages26 Initial Right Ventricular (RV) dilatation
Diagnosis

Patients with a moderate left-to-right shunt may remain asymptomatic for years. However, historical series have shown that chronic volume overload may ultimately lead to severe complications: Co
Overview

LEARN MORE: DIAGNOSIS TREATMENT
Overview

TREATMENT RANGE 4 MM TO 40 MM No other ASD closure device on the market today can match ASO’s wide range of device sizes.
Overview

SWITCH TO THE REFERRAL VIEW For more information specific to neonatology regarding PDA closure LEARN MORE: PDA Symposium 2024